アフターアワーズ： 1.21 0.01 +0.83%

MAIA Biotechnology Inc (MAIA)

概要ニュース株価時系列ディスカッション予測

MAIA Biotechnology Inc (MAIA) 最新ニュース

MAIA Biotechnology Inc (MAIA)

MAIA Biotechnology Inc (MAIA) 最新ニュース

MAIA Biotechnology reports 90.5% disease control rate in NSCLC trial - scanx.trade

MAIA Biotechnology doses first US patient in Phase 2 lung cancer trial - scanx.trade

MAIA Biotechnology files $150 million mixed shelf offering with SEC - scanx.trade

MAIA Biotechnology files resale prospectus for 751,879 shares - scanx.trade

Form S-3 Maia Biotechnology Inc For: 25 September By Investing.com - Investing.com Nigeria

MAIA Biotechnology, Inc. (MAIA) Stock Price, News, Quote & History - Yahoo! Finance Canada

MAIA Biotechnology expands pivotal Phase 3 THIO-104 NSCLC trial into Spain and Portugal - Dealroom

MAIA Biotechnology Announces Spain and Portugal Regulatory Approvals for THIO-104 Phase 3 NSCLC Trial - Quiver Quantitative

About 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there. - Stock Titan

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer - Yahoo Finance

A $2.3 million National Institutes of Health grant funds a cancer trial. MAIA doses its first U.S. patient. - Stock Titan

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial - Yahoo Finance

MAIA Biotechnology Announces Insider Share Purchases by Board Member and CEO Amid Positive Phase 3 and Phase 2 Data Updates - Quiver Quantitative

Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock - Investing.com

Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock By Investing.com - Investing.com UK

MAIA Biotechnology (NYSE: MAIA) CEO adds 73,000 shares at $1.37 - Stock Titan

Maia Biotechnology director buys $49,516 in company shares By Investing.com - Investing.com South Africa

Maia Biotechnology director buys $49,516 in company shares - Investing.com

MAIA Biotechnology Delivers Oral and Poster Presentations - GlobeNewswire

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 - Yahoo Finance

MAIA Biotechnology Inc. (MAIA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

New Form 4 - Moomoo

MAIA Biotechnology, Inc. SEC Filing (Aug 31, 2026) - Stock Titan

MAIA Biotechnology Inc. (MAIA) Key Financial Ratios – Valuation, Profitability & More - Value Research

MAIA Biotechnology Inc. (MAIA) Peer Comparison – Compare with Others - Value Research

Maia Biotechnology director Guerrero buys $2,386 in common stock - Investing.com

Price to earnings forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView

MAIA (MAIA) Latest: Declines 0.07% to $1.38 in the Latest Session; Chart Watch: the Session Ends Within the Reported Technical Boundaries at the CloseDouble Top - vinanet.vn

MAIA Biotechnology Q3 EPS Forecast Lowered by Diamond Equity - MarketBeat

MAIA (MAIA) Q2 2026 Results: EPS Does Not Reach the Reported Estimate on the Day; Post-Earnings: The Stock Records a 3.28% Increase in the Current UpdatePositive Surprise Momentum - vinanet.vn

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance

Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA - MarketBeat

Solas Capital discloses 4.9% MAIA Biotechnology (MAIA) stake in Schedule 13G/A - Stock Titan

MAIA Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Biotech Challenges - Vinanet

Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

MAIA Biotechnology Q2 Results: EPS misses estimates - scanx.trade

MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary - TradingView

MAIA Biotechnology (MAIA) Projected to Release Earnings on Monday - MarketBeat

MAIA Biotechnology Q1 2026 Earnings: EPS Beats Estimates, No Revenue ReportedMargin Compression Risk - dars.gov.et

MAIA Biotechnology, Inc. Revenue Breakdown – AMEX:MAIA - TradingView

MAIA|Maia Biotechnology Inc|Price:1.255|Chg%:+0.005 - TradingKey

Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com

Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey

MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey

Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

MAIA Biotechnology (MAIA) Gains 3.23% as Shares Push Toward $1.28 Resistance LevelForce Index - dars.gov.et

MAIAに似た銘柄